What happened between Mayne Pharma Group (ASX:MYX) and Cosette Pharmaceuticals?

Mayne Pharma Group (ASX:MYX) secured a $14.4 million payout from Cosette Pharmaceuticals following an order by the Supreme Court of New South Wales.

Why is Cosette Pharmaceuticals paying Mayne Pharma Group (ASX:MYX) $14.4 million?

The payment resolves an adverse costs order issued against Cosette after the Supreme Court of New South Wales dismissed all of its legal claims in October 2025. The bitter legal battle began in June 2025 after Cosette purportedly terminated a Scheme Implementation Deed that both pharmaceutical companies signed in February 2025.

How does the $14.4 million payment impact Mayne Pharma Group's (ASX:MYX) balance sheet?

The $14.4 million payment functions as a significant cash influx that completely covers Mayne Pharma's historical litigation expenses and adds accumulated interest. Because these funds recoup past outlays, the windfall provides an immediate boost to the company's cash position without diluting existing retail shareholders.

Is the legal dispute between Mayne Pharma (ASX:MYX) and Cosette completely over?

No, the broader legal saga is not entirely resolved despite the cost settlement. Cosette formally appealed the landmark October 2025 judgment in January 2026, meaning the core legal dispute remains active until an appellate ruling is handed down.

What are the short-term bull and bear points for Mayne Pharma (ASX:MYX) traders after this news?

The primary bull case is the successful clawback of $14.4 million in cash, which vindicates management's legal strategy and de-risks past litigation spending. The main bear case is the lingering overhang of Cosette's active appeal, which could still alter the final legal outcome if the previous judgment is overturned.

Mayne Pharma secures $14.4M legal cost payout

Written by Liezl GambePublished Jun. 5 2026Last Updated Jun. 5 2026

Mayne Pharma Group (ASX:MYX) secured a multimillion-dollar windfall, confirming the receipt of $14.4 million from Cosette Pharmaceuticals.

The multi-million-dollar payment was executed in accordance with strict orders handed down by the Supreme Court of New South Wales on May 29.

The substantial sum serves as a full recovery of Mayne Pharma’s extensive legal costs, expenses related to its formal application for costs, and accumulated interest.

This financial resolution marks yet another major milestone in a bitter, ongoing legal battle that dates back to June 2025.

The initial litigation was commenced by Mayne Pharma following Cosette’s purported termination of a scheme implementation deed, which both pharmaceutical entities had originally signed in February 2025.

The legal tide turned heavily in October 2025 when the Supreme Court delivered a decisive judgement in favour of Mayne Pharma, completely dismissing all of Cosette’s claims.

The court issued an adverse costs order against Cosette, legally compelling the company to foot Mayne Pharma’s legal bill.

While the $14.4 million payment settles the immediate cost orders, the broader legal saga is not entirely over. Mayne Pharma noted that Cosette formally appealed the landmark October 2025 judgement earlier this year in January.

The high-stakes appeal was recently heard in the Supreme Court of New South Wales, Court of Appeal, on June 2-3. The bench has currently reserved its decision.

At the time of reporting, Mayne Pharma Group’s share price was $2.30.